PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-18.39%
Negative revenue growth while CSIQ stands at 41.55%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-28.35%
Negative gross profit growth while CSIQ is at 259.47%. Joel Greenblatt would examine cost competitiveness or demand decline.
-194.50%
Negative EBIT growth while CSIQ is at 327.97%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-360.84%
Negative operating income growth while CSIQ is at 332.52%. Joel Greenblatt would press for urgent turnaround measures.
-375.90%
Negative net income growth while CSIQ stands at 121.19%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-380.00%
Negative EPS growth while CSIQ is at 100.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-18766.67%
Negative diluted EPS growth while CSIQ is at 100.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.90%
Slight or no buybacks while CSIQ is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-50.22%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-68.37%
Negative OCF growth while CSIQ is at 171.37%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-68.37%
Negative FCF growth while CSIQ is at 68.60%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-70.54%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-59.76%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-65.22%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
96.53%
OCF/share CAGR of 96.53% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-145.05%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
82.95%
Positive 3Y OCF/share CAGR while CSIQ is negative. John Neff might see a big short-term edge in operational efficiency.
-672.69%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-343.37%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
23.54%
Positive short-term CAGR while CSIQ is negative. John Neff would see a clear advantage in near-term profit trajectory.
-111.62%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-812.15%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-155.81%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.46%
Our AR growth while CSIQ is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-52.87%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
10.37%
Asset growth above 1.5x CSIQ's 6.59%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-19.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.00%
Debt growth far above CSIQ's 9.86%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-19.49%
We cut SG&A while CSIQ invests at 84.38%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.